1 / 4

Darzi Next Steps Review – Systems and Incentives Pricing Workstream

This workstream, part of the Darzi Review, focuses on systems and incentives in order to develop more effective payment mechanisms and support desired outcomes and models of care. The main questions addressed are related to the perverse incentives preventing high-quality care pathways across primary, secondary, and tertiary care, and how to fix them. Additionally, the workstream explores the potential for pricing based on therapy costs or patient pathways for CKD treatment, with a focus on building incentives for informed choice and high-quality therapy.

tgarduno
Download Presentation

Darzi Next Steps Review – Systems and Incentives Pricing Workstream

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Darzi Next Steps Review – Systems and Incentives Pricing Workstream

  2. ‘Systems and Incentives’ is one of the workstreams in the Darzi Review: the DH PbR team leads on “pricing” Key questions: Building on ‘Options for the Future of PbR’, how should PbR develop in order to support desired outcomes and models of care? What would more effective payment mechanisms look like?

  3. Issues for renal medicine 1. What are the perverse incentives preventing delivery of high quality of care pathways across primary, secondary and tertiary care as envisaged by Darzi 2. What would you do to fix it?

  4. Incentives • Should pricing be based on therapy costs for individual treatments or a ‘patient pathway’ for different stages of CKD therapy? • How would you build in incentives to ensure that patients receive the most appropriate high quality therapy based on informed choice?

More Related